Zevra Therapeutics (ZVRA) Cash from Financing Activities (2014 - 2026)

Zevra Therapeutics (ZVRA) has 13 years of Cash from Financing Activities data on file, last reported at -$52.8 million in Q1 2026.

• Quarterly Cash from Financing Activities fell 3385.87% year-over-year to -$52.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$42.3 million (down 151.33% YoY) and the FY2025 annual result came in at $12.1 million, down 85.31% from the prior year.
• Cash from Financing Activities slipped to -$52.8 million in Q1 2026, from $2.5 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $64.8 million in Q3 2024 to a low of -$52.8 million in Q1 2026.
• A 5-year average of $4.6 million and a median of $1.4 million in 2025 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities soared 7800.59% — and 2026, when it plunged 3385.87%.
• Tracing ZVRA's Cash from Financing Activities over 5 years: stood at -$325000.0 in 2022, then jumped by 1639.69% to $5.0 million in 2023, then tumbled by 84.09% to $796000.0 in 2024, then soared by 219.85% to $2.5 million in 2025, then slumped by 2174.0% to -$52.8 million in 2026.
• The last three Cash from Financing Activities figures came in at -$52.8 million (Q1 2026), $2.5 million (Q4 2025), and $6.5 million (Q3 2025), per Business Quant data.